Prediction of gestational diabetes mellitus and pre-diabetes 5 years postpartum using 75 g oral glucose tolerance test at 14-16 Weeks' gestation by Lekva, Tove et al.
1SCIENTIFIC RePoRTs |  (2018) 8:13392  | DOI:10.1038/s41598-018-31614-z
www.nature.com/scientificreports
Prediction of Gestational Diabetes 
Mellitus and Pre-diabetes 5 Years 
Postpartum using 75 g Oral Glucose 
Tolerance Test at 14–16 Weeks’ 
Gestation
Tove Lekva  1, Kristin Godang2, Annika E. Michelsen1,3, Elisabeth Qvigstad4, 
Kjersti Ringvoll Normann1,2,3, Errol R. Norwitz6,7, Pål Aukrust1,3,8,9,10, Tore Henriksen3,11, 
Jens Bollerslev2,3, Marie Cecilie Paasche Roland5,11 & Thor Ueland1,3,10
Early detection and treatment of women at risk for gestational diabetes mellitus (GDM) could improve 
perinatal and long-term outcomes in GDM women and their offspring. We explored if a 75 g oral glucose 
tolerance test (OGTT) at 14–16 weeks of gestation could identify women who will (1) develop GDM or 
give birth to large-for-gestational-age (LGA) babies in 1031 pregnant women from the STORK study 
using different diagnostic criteria (WHO1999, IADPSG2010, WHO2013, NORWAY2017) and (2) develop 
pre-diabetes 5 years postpartum focusing on first trimester β-cell function in a separate study of 300 
women from the STORK cohort. The sensitivity of the 14–16 week OGTT to identify women who would 
develop GDM or have LGA babies was low, and we could not identify alternative cut-offs to exclude 
women not at risk or identify women that could benefit from early intervention. First trimester β-cell 
function was a stronger determinant than third trimester β-cell function of predicting maternal pre-
diabetes. In conclusion, in our normal low-risk population, the 75 g OGTT at 14–16 weeks is insufficient 
to identify candidates for early treatment of GDM or identify women not likely to develop GDM or have 
LGA babies. First trimester β-cell function may predict pre-diabetes 5 years postpartum.
Gestational diabetes mellitus (GDM), defined as glucose intolerance with onset or first recognition during preg-
nancy, affects 4–18% of pregnancies. It is caused by an imbalance between insulin resistance and secretion, and 
occurs when pancreatic β-cells fail to keep up with insulin production in the face of the increasing insulin resist-
ance during pregnancy1,2. GDM is associated with obstetric complications with short- and long-term health con-
sequences for the infant and increased long-term risk of cardio-metabolic disease in the mother. Criteria used to 
diagnose GDM vary with different glucose cut-offs and one or two-step approaches, making it difficult to compare 
studies and identify those pregnancies that are truly at risk. The Hyperglycemia and Adverse Pregnancy Outcome 
(HAPO) study3 outlined a uniform set of diagnostic criteria endorsed in 2010 by the International Association of 
the Diabetes and Pregnancy Study Group (IADPSG) and, in 2013, by the World Health Organization (WHO)4. 
These criteria have been accepted by most countries throughout the world, but have been criticized because of 
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the large number of women who will have to undergo testing with implications on service provision, and the 
high number of women who will be diagnosed with GDM without have a real risk profile5. Countries such as 
the United Kingdom, Italy, and Norway perform risk factor-based screening, with only high-risk individuals 
receiving the 75 g oral glucose tolerance test (OGTT). In the United States, the American Diabetes Association 
(ADA) and the American Congress of Obstetricians and Gynecologists (ACOG) use a two-step approach with an 
initial universal screening test (50 g glucose load test) followed by a diagnostic test (100 g OGTT) at 24–28 weeks 
of gestation. Norway has recently modified their recommendations and are now using diagnostic criteria similar 
to that used in the US and Canada (Supplemental Table 1).
Treatment of GDM improves perinatal, obstetric and maternal outcomes6, but risk for long-term 
cardio-metabolic outcomes still remains high in the offspring of GDM mothers7, possibly due to prolonged expo-
sure to maternal hyperglycemia. Using current criteria, testing for GDM may not be completed until 30 weeks, 
leaving a narrow window for intervention. Thus, early detection and treatment of women at risk for GDM, ideally 
at the time of enrollment in prenatal care, could improve perinatal and long-term outcomes in GDM women and 
their offspring8,9.
We hypothesized that a 75 g OGTT at 14–16 weeks could identify women who will subsequently develop 
GDM and this was examined in a prospective cohort study using four different diagnostic criteria for GDM: the 
WHO1999, IADPSG2010, WHO2013, and the new 2017 Norway criteria. We examined multiple potential cut-
offs for early diagnosis of GDM and large for gestational age (LGA) babies and also assessed alternative markers 
of glucose metabolism derived from the OGTT as well as combinations with BMI and age. In a separate study, 
we examined the ability of first trimester β-cell function measurements to identify women with pre-diabetes at 
5-years postpartum.
Materials and Methods
We performed a secondary analysis of the STORK study, a prospective longitudinal cohort study in which 1031 
low-risk women of Scandinavian heritage were followed throughout their pregnancy and gave birth at Oslo 
University Hospital Rikshospitalet between 2002 and 200810. The exclusion criteria were multiple pregnancies, 
known pre-gestational diabetes and any severe chronic diseases (lung, cardiac, gastrointestinal or renal). Each 
pregnant woman had four study-related antenatal visits at weeks 14–16, 22–24, 30–32, and 36–38. A 75 g OGTT 
was performed on all women at 14–16 and 30–32 weeks of gestation. All women were invited to participate in 
a 5-year postpartum follow-up study of which 300 from the original study agreed11. Written informed consent 
was obtained from all study participants. All clinical investigations were conducted in accordance with the prin-
ciples enshrined in the Declaration of Helsinki. The study was approved by the Regional Committee for Medical 
Research Ethics of Southern Norway in Oslo, Norway.
Measurements of glucose and insulin from OGTT. All 75 g OGTTs were performed in the morning 
after an overnight fast and glucose levels measured as previously reported11. Briefly, venous blood was drawn 
in gel tubes, allowed to clot for 30 min, thereafter centrifuged for 10 min 3000 g, serum separated and stored at 
−80 °C. Glucose was measured in serum samples collected at antenatal visits at 14–16 and 30–32 weeks and fro-
zen until analysis, using the hexokinase method at an accredited clinical chemistry laboratory at Oslo University 
Hospital (Cobas 6000 from Roche). For the 5-year follow-up visit, fasting glucose measurements were collected 
using an Accu-check Sensor glucometer (Roche Diagnostics), using venous EDTA blood analyzed on site, as 
previously reported11. Insulin levels were assayed in duplicate (RIA, DPC, Los Angeles, CA, USA) as previously 
reported11,12.
Diagnosis of GDM and pre-diabetes. GDM was diagnosed using four separate criteria: (i) the WHO1999 
criteria (2 h plasma glucose ≥7.8 mmol/L), (ii) the IADPSG2010 criteria (fasting plasma glucose (FPG) 5.1–
6.9 mmol/L, 1 h plasma glucose ≥10.0 mmol/L or 2 h plasma glucose 8.5–11.0 mmol/L) and in addition FPG 
5.1–6.9 mmol/L in early pregnancy, (iii) the WHO2013 criteria (fasting plasma glucose (FPG) 5.1–6.9 mmol/L, 
1 h plasma glucose ≥10.0 mmol/L or 2 h plasma glucose 8.5–11.0 mmol/L, at any time in pregnancy) and (iv) 
Norway2017 criteria (FPG ≥ 5.3 mmol/L or 2 h plasma glucose ≥9.0 mmol/L)13 following a 75 g oral glucose load. 
Pre-diabetes was diagnosed at the 5-year follow-up visit using the following criteria: FPG 5.6–6.9 mmol/L or 2 h 
plasma glucose 7.8–11.0 mmol/L after 75 g OGTT14.
Insulin sensitivity was measured with the Matsuda index 10 000/√ of (fasting glucose (mmol/L) × fasting 
insulin (mU/L) × (mean glucose (mmol/L) × mean insulin (mU/L)) during 75 g OGTT. This index is a meas-
ure of whole body insulin sensitivity that has been validated against the euglycemic-hyperinsulinemic clamp15. 
β-cell function was assessed with the insulin secretion-sensitivity index (ISSI-2) (area under the curve insu-
lin(mU/L)0–120/glucose(mmol/L)0–120 × Matsuda), validated against the disposition index from the intravenous 
glucose tolerance test16. HOMA-IR was calculated as fasting insulin (mU/L) × fasting glucose (mmol/L)/22.5, 
as described by Matthews et al.17. Insulin secretion was assessed by the insulinogenic index (IGI: (Ins30–Ins0)/
(Glu30–Glu0)).
Statistical analysis. Statistical analyses were conducted using SPSS for Windows, version 21.0. Data are 
expressed as mean (SD) when normally distributed and median (25th, 75th percentile) when skewed. Comparison 
between women with GDM and non-GDM were performed using t-test or Mann–Whitney’s U depending on 
distribution, and χ2 test for categorical variables. Accuracy was represented using the terms sensitivity, specific-
ity, positive predictive value (PPV), and negative predictive value (NPV) calculated as follows: Sensitivity = True 
positive/(True positive + False negative), Specificity = True negative/(False positive + True negative), Positive 
predictive value (PPV) = True positive/(True positive + False positive), Negative predictive value (NPV) = True 
negative/(False negative + True negative). The association between glucose levels and accuracy terms was assessed 
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using third order polynomial regression. Receiver operator characteristics (ROC) analysis was used to determine 
the optimum cut-off values for some markers. p < 0.05 was considered statistically significant.
Results
Of the 1031 women in the study with representative OGTT results at 30–32 weeks, we identified 132 (13.4%) 
women who developed GDM based on the WHO1999 criteria, 241 (24.5%) based on the IADPSG2010, 244 
(24.8%) based on the WHO2013 criteria, and 91 (9.2%) based on Norway criteria compared to 853, 744, 741, and 
896 control women without GDM, respectively. Their clinical characteristics are provided in Table 1. In general, 
women who developed GDM were older, had higher BMI, higher blood pressure (BP), and higher proportion 
of LGA babies. As expected, we found higher insulin resistance and area under the curve (AUC) for glucose and 
insulin, and lower insulin sensitivity and β-cell function, as assessed by insulin secretion-sensitivity index, in 
women diagnosed with GDM at weeks 14–16 and 30–32 (Table 1). The glucose and insulin measurements from 
the OGTT at weeks 14–16 and 30–32 are presented in Fig. 1. The correlation of fasting glucose and the four 
post-load glucose measurements during OGTT at week 14–16 and corresponding measurement at week 30–32 
were, r = 0.54, r = 0.48, r = 0.54, r = 0.58 and r = 0.50, respectively (p < 0.001).
Early diagnosis of GDM when applying diagnostic criteria at 14–16 weeks. Based on the results 
of the 75 g OGTT at 14–16 weeks, we identified 20 (2.0%), 118 (12.5%), 119 (12.6%) and 46 (4.7%) women with 
GDM, using the WHO1999, IADPSG2010, WHO2013, and 2017 Norwegian criteria, respectively. The FPG in 
early pregnancy is included in the IADPSG2010 criteria and the OGTT used to diagnose GDM could be meas-
ured at any time using the WHO2013 criteria, so these criteria are using the 14–16 weeks OGTT as well. The PPV 
of this early OGTT for identifying women diagnosed with GDM was 95% using the WHO1999 criteria, 87.3% 
using the IADPSG2010, 89.9% using the WHO2013 criteria, and 47.8% using the 2017 Norwegian criteria. The 
NPV was 88.2%, 84.3%, 84.4% and 92.7%, respectively. The sensitivity and specificity were 14.8% and 99.9% for 
the WHO1999 criteria, 44.2% and 97.9% for the IADPSG2010, 45.3% and 98.3% for the WHO2013 criteria, and 
25.0% and 97.2% for the 2017 Norwegian criteria (Supplemental Table 2).
WHO 1999 (2 h glucose ≥7.8)
IADPSG 2010 $ (Fasting, 1 h, or 2 h 
glucose ≥5.1, ≥10, ≥8.5)
WHO 2013# (Fasting, 1 h, or 2 h 
glucose ≥5.1, ≥10, ≥8.5)
Norway 2017 (Fasting or 2 h glucose, 
≥5.3, ≥9.0)
Non-GDM GDM Non-GDM GDM Non-GDM GDM Non-GDM GDM
N= 853 132 744 241 741 244 896 91
Age (years) 31.2 (3.8) 32.0 (4.3)* 31.0 (3.7) 32.0 (4.3)* 31.0 (3.7) 32.0 (4.3)* 31.0 (3.8) 31.8 (4.5)
Height (cm) 169 (6) 168 (5)* 169 (6) 168 (6) 169 (6) 168 (6) 169 (6) 169 (6)
Fam history diabetes 
n (%) 87 (10.2) 12 (9.1) 73 (9.8) 25 (10.4) 73 (9.9) 25 (10.2) 93 (10.4) 6 (6.6)
Primipara n (%) 456 (53.5) 67 (50.8) 415 (56.2) 111 (46.6) * 413 (56.2) 112 (46.5)* 485 (54.6) 40 (44.4)
Preeclampsia n (%) 28 (3.3) 7 (5.3) 25 (3.4) 10 (4.1) 25 (3.4) 9 (3.7) 32 (3.6) 3 (3.3)
LGA/SGA (%) 107 (12.5)/62 (7.3) 28 (21.2)*/8 (6.1) 82 (11.1)/62 (8.4) 53 (22.0)*/9 (3.7) 81 (11.0)/62 (8.4) 54 (22.1)*/9 (3.7) 112 (12.5)/66 (7.4) 23 (25.3)*/5 (5.5)
Currently smoking 
n (%) 17 (2.0) 6 (4.5) 14 (2.4) 9 (5.1) 14 (2.4) 10 (5.5)* 18 (2.6) 5 (7.8)*
Previous smoker n (%) 183 (21.5) 37 (28.0) 156 (21.4) 63 (27.2) 156 (21.5) 63 (26.9) 193 (22.0) 27 (31.4)*
BMI (kg/m2)a 23.8 (21.7, 26.0) 27.9 (25.0, 31.1)* 23.5 (21.5, 25.7) 25.5 (23.1, 28.5)* 23.5 (21.5, 25.7) 25.4 (23.1, 28.4)* 23.7 (21.7, 26.0) 26.4 (23.8, 30.5)*
BMI (kg/m2)b 26.5 (24.3, 29.1) 27.9 (25.0, 31.1)* 26.2 (24.0, 28.6) 28.4 (26.2, 31.1)* 26.2 (24.0, 28.6) 28.4 (26.2, 31.1)* 26.5 (24.2, 28.9) 29.0 (26.4, 32.4)*
Systolic BP (mmHg)a 110 (100, 120) 110 (105, 120)* 110 (100, 120) 110 (105, 120)* 110 (100, 120) 110 (105, 120)* 110 (100, 120) 115 (110, 120)*
Systolic BP (mmHg)b 110 (105, 120) 110 (110, 120) 110 (105, 120) 115 (110, 120)* 110 (105, 120) 115 (110, 120)* 110 (105, 120) 115 (110, 120)*
Diastolic BP (mmHg)a 65 (60, 70) 70 (60, 70)* 65 (60, 70) 70 (60, 70)* 65 (60, 70) 70 (60, 70)* 69 (60, 70) 70 (60, 70)*
Diastolic BP (mmHg)b 70 (60, 75) 70 (60, 75) 70 (60, 75) 70 (60, 75)* 70 (60, 75) 70 (60, 75)* 70 (60, 75) 70 (65, 75)*
Insulin sensitivitya 210 (149, 297) 135 (89, 203)* 217 (155, 307) 141 (93, 209)* 217 (156, 308) 140 (92, 210)* 206 (148, 293) 114 (81, 197)*
Insulin sensitivityb 114 (80, 169) 70 (49, 96)* 120 (84, 175) 71 (51, 101)* 120 (84, 174) 72 (51, 101)* 113 (79, 165) 59 (43, 79)*
Insulin resistancea 0.75 (0.50, 1.12) 1.04 (0.73, 1.71)* 0.71 (0.46, 1.05) 1.08 (0.77, 1.78)* 0.71 (0.46, 1.05) 1.07 (0.77, 1.78) * 0.76 (0.5, 1.12) 1.21 (0.84, 1.84) *
Insulin resistanceb 1.12 (0.73, 1.73) 1.80 (1.19, 2.54)* 1.05 (0.69, 1.58) 1.84 (1.24, 2.61)* 1.05 (0.69, 1.58) 1.84 (1.24, 2.62)* 1.12 (0.74, 1.68) 2.30 (1.78, 3.62)*
β-cell functiona 1140 (916, 1497) 805 (608, 1055)* 1190 (953, 1543) 821 (653, 1062)* 1193 (958, 1543) 817 (652, 1061)* 1133 (914, 1487) 737 (617, 908)*
β-cell functionb 927 (723, 1187) 574 (456, 687)* 980 (780, 1247) 606 (485, 719)* 980 (781, 1247) 606 (484, 719)* 917 (719, 1165) 460 (402, 550)*
AUC glucosea 21.1 (18.7, 24.1) 26.2 (22.7, 30.7)* 20.6 (18.4, 23.7) 24.5 (22.1, 27.8)* 20.6 (18.5, 23.7) 24.6 (22.1, 28.0)* 21.3 (18.8, 24.2) 25.9 (22.7, 29.6)*
AUC glucoseb 26.5 (23.4, 29.2) 34.1 (31.7, 36.3)* 26.0 (23.1, 28.6) 32.9 (29.2, 35.4)* 26.0 (23.1, 28.6) 32.8 (29.2, 35.3)* 26.8 (23.7, 29.7) 34.6 (30.5, 37.8)*
AUC insulina 810 (605, 1156) 1099 (822, 1624)* 795 (596, 1125) 1006 (768, 1520)* 792 (597, 1120) 1006 (767, 1522)* 822 (615, 1163) 1164 (768, 1661)*
AUC insulinb 1528 (1089, 2075) 2046 (1400, 2741)* 1478 (1085, 2020) 1927 (1338, 2684)* 1478 (1087, 2017) 1912 (1316, 2684)* 1538 (1105, 2126) 1912 (1371, 2766)*
Table 1. Characteristics of mothers with GDM versus non-GDM. Data given as mean (SD) when normal 
distributed and median (25th, 75th) when skewed distributed. *p < 0.05 aweeks 14–16, bweeks 30–32. #At any 
time in pregnancy. $Fasting glucose 5.1–6.9 mmol/L in early pregnancy is also used to diagnose GDM.
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Examination of multiple cutoffs in the OGTT for early diagnosis of GDM. Compared with meas-
urements at 14–16 weeks, measurements at 30–32 weeks in women with GDM (diagnosed at 30–32 weeks) 
were an average of 8.2% higher at baseline (i.e., fasting levels), 36.0% higher at 60 minutes, and 35.0% higher at 
120 minutes during OGTT, regardless of the diagnostic criteria used. To evaluate the effect of lower diagnostic 
cut-offs and adjust for gestational age difference, we assessed the ability of the 75 g OGTT at 14–16 weeks to pre-
dict GDM when incrementally down adjusting the cut-offs by 1% (fasting) and 4% (60 and 120 minutes) from the 
original diagnostic criteria. As shown in Fig. 2A, the juncture between sensitivity and specificity (i.e. when they 
cross) for diagnosing GDM at 14–16 weeks was around a 7–9% and 28–32% decrease in fasting and 60/120 min-
utes glucose, respectively, giving a sensitivity and specificity around 70%. Approximately 80% sensitivity could 
be achieved when lowering fasting glucose by 8% and 60/120 minutes glucose by 32% for IADPSG2010 and 
WHO2013 while a slightly larger reduction (fasting glucose 10% and 60/120 minute glucose 40%) was needed for 
WHO1999 and Norway2017. However, at this extensive decrease in the glucose thresholds, around 40–50% of the 
population would be classified as at risk. Similar results were obtained when plotting test characteristics against 
percentiles of glucose derived from OGTT (from the total population) at 14–16 weeks (Fig. 2B).
Combination of age and BMI with OGTT at 14–16 weeks in early diagnosis of GDM. To assess the 
impact of combining additional criteria together with glucose data from the OGTT at 14–16 weeks in predicting 
GDM at 30–32 weeks we evaluated combinations with BMI using a cut-off of 30 and with age using a cut-off of 
35. For BMI, 87 women (9%) had a BMI over 30 and for age, 19.4% were 35 or older. The diagnostic accuracy of 
these measures alone varied somewhat depending on diagnostic criteria and is given in Supplemental Tables 3 
and 4. Supplemental Fig. 1 shows how combining these measures with data from the OGTT as described above. 
Across the different diagnostic criteria, addition of BMI and/or age increased sensitivity modestly when using 
high cut-offs from the OGTT but there was little overall gain when evaluating lower glucose cut-offs. Specificity 
decreased accordingly with inclusion of these additional data and the PPV was poor in all models.
Evaluation of alternative markers derived from the OGTT for early prediction of GDM. We next 
assessed the discriminatory properties of single measurements and AUC of glucose and insulin from the 14–16 
week OGTT to predict GDM at 30–32 weeks using ROC analysis. As shown in Supplemental Fig. 2, the accuracy 
varied for the different glucose measurements, but was in general fair for most measures (i.e., AUC 0.7–0.8), with 
poorer performance for insulin. The best performance was in general achieved for β-cell function and AUC cal-
culated for glucose during OGTT, although fasting glucose at 14–16 weeks had a high AUC for IADPSG2010 and 
WHO2013 since it is included in the diagnostic criteria. Figure 3 shows the different accuracy measures plotted 
against percentiles of β-cell function (panel A), AUC glucose (panel B) and fasting glucose (panel C) determined 
in the whole population. The cut-off to achieve a sensitivity of >80% using β-cell function or AUC glucose to 
predict GDM at 30–32 weeks is around the 50th percentile, although it was higher for AUC glucose using the 2017 
Norwegian criteria. At this cut-off, specificity is around 60% and the PPV is between 20–40%. Similarly, the sen-
sitivity achieved using the 50th percentile for fasting glucose (Fig. 3C) was 70–75% for the different criteria, with 
specificity around 50% and PPV between 20–30%. As fasting glucose at 14–16 weeks is included in the criteria for 
IADPSG2010 and WHO2013, a better PPV was achieved with these criteria.
Figure 1. OGTT data. Glucose and insulin levels during OGTT at weeks 14–16 and 30–32 in pregnancy 
between GDM (black circles) and non-GDM (white circles). Data presented as mean (95% CI).
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Predicting large for gestational age (LGA) infants using early OGTT data. 142 (13.8%) of the 
women gave birth to a LGA infant. We found 35%, 23.7% and 18.6% of the GDM diagnosed at 14–16 weeks 
(diagnostic criteria using at standard 24–28 weeks) to deliver LGA babies diagnosed with the WHO1999, 
IADPSG2010/WHO2013 and Norway2017 criteria. This gave an OR of 3.24 (95% CI, [1.27–8.29]) p = 0.014 for 
WHO1999, OR 1.98 (95%CI, [1.23–3.20])) p = 0.005 for IADPSG2010/WHO2013 and 1.36 (95%CI, [0.61–2.99]) 
p = 0.452 for the Norway2017 criteria. The diagnostic accuracy for detecting LGA babies by applying the different 
diagnostic criteria at 14–16 weeks is given in Supplemental Table 5 and shows a sensitivity of 5–6% for WHO1999 
and Norway2017 criteria, and a sensitivity of 20.1% using IADPSG2010/WHO2013 criteria. Figure 4 shows the 
diagnostic accuracy when lowering the thresholds of these criteria. For WHO1999 and Norway2017, sensitivity 
remained quite poor, while 80% sensitivity could be achieved for IADPSG2010/WHO2013 when lowering fasting 
glucose by 10% and 60/120 minutes glucose by 40% but at this extensive decrease in glucose more than half of the 
population would have a positive test.
Second study: Predicting pre-diabetes using early estimates of β-cell function. We have previ-
ously identified β-cell dysfunction in the third trimester as a strong predictor of pre-diabetes at 5-years postpar-
tum11. In this study, we examined whether early estimates of β-cell function could predict pre-diabetes 5 years 
after the index pregnancy, using a separate dataset of 300 women who completed the 5-year follow-up visit, of 
which 20 had pre-diabetes. Evaluated as a continuous variable, log β-cell function at 14–16 weeks could identify 
women at risk of developing pre-diabetes (OR 0.34 [95% CI, 0.20–0.58], p < 0.001 per SD change). Similar values 
were obtained for β-cell function at 30–32 weeks (OR 0.42 [0.26–0.67], p < 0.001 per SD change). A comparison 
of both variables revealed that β-cell function at 14–16 weeks was a stronger predictor (14–16 weeks: OR 0.41 
[0.22–0.76], p = 0.005 per SD change vs 30–32 weeks: OR 0.76 [0.42, 1.37], p = 0.36 per SD change). No colinear-
ity issues were identified when including β-cell function at 14–16 and 30–32 weeks in the same model (tolerance 
0.60, VIF 1.68).
We next evaluated if the combination of early β-cell dysfunction and later GDM was associated with higher 
risk for future pre-diabetes. The association with pre-diabetes was dependent on diagnostic criteria. No asso-
ciation between GDM and pre-diabetes using the WHO1999 criteria was detected. For IADPSG2010 and 
WHO2013, the combination with GDM did not enhance prediction of pre-diabetes (i.e. lower total Wald score). 
However, when the interaction between β-cell function and GDM was included in the model, the association 
Figure 2. Test characteristics of different cut-offs of glucose from the 75 g OGTT at 14–16 weeks. Sensitivity, 
specificity, PPV and NPV across the different GDM diagnostic criteria using (A) 1% (fasting) and 4% (60 and 
120 minutes) decreases from standard 30–32 week OGTT cut-offs, and (B) percentiles of glucose derived from 
the total population at 14–16 weeks in pregnancy. In (A) the % decrease in glucose is shown in italic. Vertical 
text shows the actual glucose values at the different time-points.
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Figure 3. Test characteristics of different cut-offs based on percentiles obtained from the total population for 
β-cell function, AUC glucose, and fasting glucose from the 75 g OGTT at 14–16 weeks. Sensitivity, specificity, 
PPV and NPV across the different GDM diagnostic criteria using 5% changes in percentiles for (A) β-cell 
function, (B) AUC glucose and (C) fasting glucose at 14–16 weeks in pregnancy. The percentiles are shown in 
italic and vertical text shows the cut-off levels at the different time-points.
Figure 4. Test characteristics of different cut-offs of glucose from the 75 g OGTT at 14–16 weeks for identifying 
LGA children. Sensitivity, specificity, PPV and NPV across the different GDM diagnostic criteria using 1% 
(fasting) and 4% (60 and 120 minutes) decreases from standard 30–32 week OGTT cut-offs. The % decrease in 
glucose is shown in italic. Vertical text shows the actual glucose values at the different time-points.
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improved. For Norway2017, β-cell function and GDM were associated with future pre-diabetes with a combined 
Wald score similar to β-cell function alone (Supplemental Table 6).
Discussion
Early detection of GDM could enhance the opportunity for interventions to improve maternal and neonatal out-
comes. We evaluated the ability of measurements obtained from 75 g OGTT performed at 14–16 weeks in normal 
low-risk pregnancies to predict a diagnosis of GDM at 30–32 weeks. While information from the OGTT had a 
potential to identify women who will develop GDM, applying the original GDM criteria early in pregnancy had 
a very poor sensitivity and while specificity was high, the majority of GDM women would be missed, limiting 
its usefulness both as a screening tool to identify women for later follow-up and for selecting women who would 
benefit from early intervention, as a substantial number of non-GDM women would need to be treated. Lowering 
the diagnostic cut-offs, combining with other diagnostic criteria such as BMI and age, or assessing alternative 
measures of glucose metabolism did not enhance diagnostic accuracy in a clinically useful way. The diagnostic 
accuracy for identifying LGA children was poorer than for GDM. Our data obtained from a prospectively sam-
pled cohort do not support early testing for GDM in normal low-risk pregnancies using OGTT. In the second 
study, early estimates of β-cell function predicted pre-diabetes at 5 years postpartum.
Previous studies investigating fasting glucose in early pregnancy using ROC analysis to predict future 
GDM18,19 found AUC between 0.67 and 0.72, with a high sensitivity (80%) but a poor specificity (high false pos-
itive rate of 53–57%). These studies concluded that fasting glucose in early pregnancy is an inefficient screening 
test for GDM. Our ROC analysis showed an AUC of 0.64–0.76 with a sensitivity of 65–70% and a false positive 
rate of 24–47% for fasting glucose, depending on the diagnostic criteria used, which is consistent with these prior 
publications. Additional studies have looked at glucose measurements at other time-points during the OGTT 
to see whether these might yield better diagnostic performance. Phaloprakarn et al.20 found that the 1 h glucose 
level with a cut-off value of 8.6 mmol/L gave a good diagnostic accuracy, but with low specificity (64.3%) and a 
poor PPV (38.9%). They concluded that this too was an inappropriate test to identify women who were likely to 
develop GDM later in pregnancy. In our study, applying the cut-offs of different criteria for GDM diagnosis early 
in pregnancy revealed a high specificity, although many cases of GDM would be missed due to the low sensitivity. 
Increasing sensitivity by lowering the cut-offs of glucose measurements at baseline (fasting), 60 and 120 minutes, 
revealed that a modest sensitivity of around 40–70% could be achieved. The association between other measures 
derived from the OGTT at 14–16 weeks and a later GDM diagnosis varied somewhat, but in general β-cell func-
tion and AUC glucose performed best but gave similar diagnostic performance as using cut-off from the OGTT. 
Previously, the insulinogenic index has been associated with postpartum glucose intolerance21 and in the present 
study, early assessment of insulinogenic index was associated with a GDM diagnosis later in pregnancy but did 
not perform as well as other indices calculated from the OGTT. Thus, to obtain this modest sensitivity, 40–50% 
of the population would be identified as at risk and require additional testing later in pregnancy. Such a strat-
egy—namely, early OGTT screening to exclude women at very low risk, followed by rescreening in a proportion 
of women—would markedly increase the total number and burden of OGTTs performed and an unacceptable 
proportion of GDM women would be missed. Furthermore, to obtain a high specificity for identifying women 
who could benefit from early intervention, a substantial number of non-GDM women would also be treated.
Previous studies evaluating the ability for early OGTT data to predict GDM have focused on one diagnostic 
criteria, often in high-risk patients and have not thoroughly evaluated the different diagnostic accuracy meas-
ures of glucose data. We extend these previous studies by evaluating different diagnostic criteria and cut-offs for 
glucose during OGTT and integrated measure of glucose metabolism in a large cohort of prospectively sampled 
apparently healthy women. Thus, data obtained from OGTT early in pregnancy seem inadequate to identify can-
didates both for screening purposes and early treatment of GDM. Combination of early OGTT data and demo-
graphics such as BMI and age increased sensitivity and showed some merit for all criteria except the WHO1999 
criteria and combinations of early OGTT data in combination with other biomarkers should be pursued in future 
studies. Although fasting glucose performed less well than measures calculated from the OGTT, it did not per-
form that much poorer when evaluated as a screening test to exclude the likelihood of developing GDM. Due to 
the simplicity of obtaining a fasting glucose sample, we cannot exclude that some benefit could be achieved with 
a strategy utilizing early measurement of fasting glucose or use of other clinical data in combination with OGTT 
data followed by an OGTT later in pregnancy.
A third trimester OGTT remains the “gold standard” for the diagnosis of GDM. The utility of a screening test 
for GDM is highly debated and many questions remain unanswered, such as: Should we screen? Should we use a 
one or two-step approach? What is the most cost effective approach? What biochemical screening test is best?22. 
The different international diagnostic criteria used and the ongoing debate on which should be the “gold stand-
ard” complicates comparison of studies and research for improving care for women with GDM. In the present 
study we employed four different criteria for GDM diagnosis, and regardless of the criteria used, our data suggest 
that an early OGTT has limited clinical benefit. The IADPSG2010/WHO2013 was adopted by many after the 
HAPO study established a relationship between maternal hyperglycemia and adverse outcomes, in particular 
LGA3. Iwama et al. did not identify a strong association between data obtained from an early OGTT and LGA23. 
Our study shows that the WHO1999 and in particular the IADPSG2010/WHO2013 criteria are associated with 
LGA also when applied early in pregnancy. However, similar to establishing an early GDM diagnosis, the diag-
nostic accuracy is quite poor and clinical usefulness limited.
A diagnosis of GDM is associated with increased risk of developing type 2 diabetes later in life24. We and 
others11,25 have identified poor β-cell function in the second and/or third trimester as a predictor of pre-diabetes 
during long-term follow-up. A recent meta-analysis identified an association between early diagnosis of GDM 
and risk of type 2 diabetes26, suggesting that the link between GDM and risk of type 2 diabetes may manifest early 
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in pregnancy. The second part of the present study supports this assertion and shows that declining β-cell func-
tion already in the first trimester is associated with increased risk for pre-diabetes at 5-years postpartum, and is an 
even stronger predictive test than β-cell function estimated in the third trimester. Furthermore, the combination 
of a later GDM diagnosis using the IADPSG2010/WHO2013 and early β-cell function was associated with an 
even higher risk of pre-diabetes. While it is not yet clear whether early intervention during pregnancy can prevent 
the development of future type 2 diabetes in GDM women, such information could be useful in raising awareness 
of increased long-term risk. Indeed, future studies that examine if early intervention based on impaired β-cell 
function in the first trimester could prevent development of type 2 diabetes could be warranted.
Limitations to our study include a modest sample size and loss of participants in the follow-up study. The 
study was collected in a city and included only women with Scandinavian heritage and our findings may therefore 
not apply to all demographics and ethnicities. The diagnosis of the GDM was performed later than the standard 
protocol, at 30–32 weeks and not at 24–28 weeks as recommended, although the prevalence of GDM suggests that 
this is an average risk cohort when it comes to GDM risk. In Norway an early HbA1c (before 16 weeks gestation) 
is suggested to be analyzed in women with risk factors, since this marker has been shown promising at predicting 
GDM27. Unfortunately we do not have HbA1c data in this cohort and are not able to evaluate the performance of 
HbA1c. Finally, our findings do not apply to high risk populations and we cannot exclude that there is informa-
tion in early OGTTs (e.g. shape information from glucose curves) that can be utilized to enhance early detection 
of GDM.
In conclusion, our data in a normal low-risk population, suggest that a 75 g OGTT at 14–16 weeks is not suit-
able to be used as a diagnostic or screening test to diagnose the women who are likely to develop GDM later or 
exclude women that are not likely to develop GDM later. However, it may give information about which women 
who will develop pre-diabetes and possibly type 2 diabetes. The uncertain clinical benefit and increased resources 
needed to perform an OGTT instead of a simple fasting glucose measurement, as well its inability to predict 
woman who will develop GDM, makes it questionable if performing routine OGTT early in normal low-risk 
pregnancy can be justified at this time.
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information file).
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